CORONAVIRUS INFECTION: PROSPECTS OF MONTELUKAST AS A THERAPEUTIC AND PROPHYLACTIC AGENT
https://doi.org/10.34822/2304-9448-2022-2-69-73
Abstract
The study aims to present the pathogenetic reasoning for using Montelukast in treatment of a new coronavirus infection. Materials and methods. The publications of foreign and Russian authors, reviews of randomized controlled trials from various sources of scientific literature, including PubMed, CyberLeninka, eLibrary, etc., were studied using such keywords as SARS-CoV-2, COVID-19, leukotriene receptor, leukotriene receptor antagonist, and Montelukast. The search depth was 10 years. Results. A wide variety of modern research is focused on the development of various therapeutic approaches for treatment of COVID-19 (coronavirus infection) that has affected many people all around the world. Thus, the study pays special attention to Montelukast. Both its performance as a safe drug for bronchial asthma and as a potential antiviral drug for severe acute respiratory syndrome caused by SARS-CoV-2 should be studied.
About the Authors
A. L. Markovskaya
Chita State Medical Academy, Chita
Russian Federation
Russian Federation
Assistant Professor
E-mail: anzhelika_petrova_1992@mail.ru
N. L. Potapova
Chita State Medical Academy, Chita
Russian Federation
Russian Federation
Candidate of Sciences (Medicine)
E-mail: nataliapotap@yandex.ru
Yu. L. Mizernitsky
N. I. Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
Honored Worker of Health Care of the Russian Federation, Doctor of Sciences (Medicine), Professor
E-mail: yulmiz@mail.ru
References
1. Hu B., Guo H., Zhou P., Shi Z. L. Characteristics of SARS-CoV-2 and COVID-19 // Nat Rev Microbiol. 2021. Vol. 19, Is. 3. P. 141–154. DOI 10.1038/s41579-020-00459-7.
2. Mason R. J. Pathogenesis of COVID-19 from a Cell Biology Perspective // Eur Respir J. 2020. Vol. 55, Is. 4. P. 2000607.DOI 10.1183/13993003.00607-2020.
3. Pedersen S. F., Ho Y.-C. SARS-CoV-2: a Storm is Raging // J Clin Invest. 2020. Vol. 130, Is. 5. P. 2202–2205. DOI 10.1172/JCI137647.
4. Aigner L., Pietrantonio F., Bessa de Sousa D. M. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic // Front Mol Biosci. 2020. Vol. 7. P. 610132. DOI 10.3389/ fmolb.2020.610132.
5. Мизерницкий Ю. Л. Патогенетическое обоснование применения Монтелукаста (Синглона) при острых респираторных вирусных инфекциях с бронхообструктивным синдромом у детей раннего и дошкольного возраста // Рос. вестник перинатологии и педиатрии. 2020. № 65 (6). С. 129–132. DOI 10.21508/1027-4065-2020-65-6-129-132.
6. Fidan C., Aydoğdu A. As a Potential Treatment of COVID-19: Montelukast // Med Hypotheses. 2020. Vol. 142. P. 109828. DOI 10.1016/j.mehy.2020.109828.
7. Chen G., Wu D., Guo W. et al. Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019 // J Clin Invest. 2020. Vol. 130, Is. 5. P. 2620–2629. DOI 10.1172/JCI137244.
8. Al-Tameemi K., Kabakli R. Novel Coronavirus (2019-NCoV): Disease Briefings // Asian J Pharm Clin Res. 2020. Vol. 13, Is. 5. P. 22–27. DOI 10.22159/ajpcr.2020.v13i5.37436.
9. Arabi Y. M., Murthy S., Webb S. COVID-19: A Novel Coronavirus and a Novel Challenge for Critical Care // Intensive Care Med. 2020. Vol. 46, Is. 5.P. 833–836. DOI 10.1007/s00134-020-05955-1.
10. Tortorici M. A., Veesler D. Structural Insights into Coronavirus Entry // Adv Virus Res. 2019. Vol. 105. P. 93–116. DOI 10.1016/ bs.aivir.2019.08.002.
11. Brielle E. S., Schneidman-Duhovny D., Linial M. The SARS-CoV-2 Exerts a Distinctive Strategy for Interacting with the ACE2 Human Receptor // Viruses. 2020. Vol. 12, Is. 5. P. 497. DOI 10.3390/v12050497.
12. Chen C.-Y., Deng Q.-X., Dai S.-Q. Remdesivir for Severe Acute Respiratory Syndrome Coronavirus 2 Causing COVID-19: An Evaluation of the Evidence // Travel Med Infect Dis. 2020. Vol. 35. P. 101647. DOI 10.1016/j.tmaid.2020.101647.
13. Dey M., Singh R. K. Possible Therapeutic Potential of Cysteinyl
14. Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19 // Pharmacology. 2021. Vol. 106, № 9-10. P. 469–476. DOI 10.1159/000518359.
15. Al-Kuraishy H. M., Al-Gareeb A. I., Almulaiky A. Q., Cruz-Martins N., Batiha G. E. Role of Leukotriene Pathway and Montelukast in Pulmonary and Extrapulmonary Manifestations of COVID-19: The Enigmatic Entity // Eur J Pharmacol. 2021. Vol. 904. P. 174196. DOI 10.1016/j.ejphar.2021.174196.
16. Zhang X., Tan Y., Ling Y. et al. Viral and Host Factors Related to the Clinical Outcome of COVID-19 // Nature. 2020. Vol. 583. P. 437–440. DOI 10.1038/s41586-020-2355-0.
17. Zayed N. E., Abbas A., Lutfy S. M. Criteria and Potential Predictors of Severity in Patients with COVID-19 // Egypt J Bronchol. 2022. Vol. 16. P. 11. DOI 10.1186/s43168-022-00116-y.
18. Diao B., Wang C., Tan Y. et al. Reduction and Functional Exhaustion of
19. T Cells in Patients with Coronavirus Disease 2019 (COVID-19) // Front Immunol. 2020. Vol. 11. P. 827. DOI 10.3389/fimmu.2020.00827.
20. Ganji A., Farahani I., Khansarinejad B., Ghazavi A., Mosayebi G. Increased Expression of CD8 Marker on T-Cells in COVID-19 Patients // Blood Cells Mol Dis. 2020. Vol. 83. P. 102437. DOI 10.1016/j.bcmd.2020.102437.
21. Hariharan A., Hakeem A. R., Radhakrishnan S., Reddy M. S., Rela M. The Role and Therapeutic Potential of NF-Kappa-B Pathway in Severe COVID-19 Patients // Inflammopharmacology. 2021. Vol. 29, Is. 1. P. 91–100. DOI 10.1007/s10787-020-00773-9.
22. Hadjadj J., Yatim N., Barnabei L. et al. Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients // Science. 2020. Vol. 369, No. 6504. P. 718–724. DOI 10.1126/science.abc6027.
23. Kandasamy M. NF-κB Signalling as a Pharmacological Target in COVID-19: Potential Roles for IKKβ Inhibitors // Naunyn Schmiedebergs Arch Pharmacol. 2021. Vol. 394, Is. 3. P. 561–567. DOI 10.1007/s00210-020-02035-5.
24. Мизерницкий Ю. Л., Сулайманов Ш. А. Антилейкотриеновые препараты в современной педиатрической практике // Рос. вестник перинатологии и педиатрии. 2019. № 64 (4). С. 128–132. DOI 10.21508/1027-4065-2019-64-4-128-132.
25. Nagao M., Ikeda M., Fukuda N. et al. Early Control Treatment with Montelukast in Preschool Children with Asthma: A Randomized Controlled Trial // Allergol Int. 2018. Vol. 67, Is. 1. P. 72–78. DOI 10.1016/j.alit.2017.04.008.
26. Wahn U., Dass S. B. Review of Recent Results of Montelukast Use as a Monotherapy in Children with Mild Asthma // Clin Ther. 2008. Vol. 30. P. 1026–1035. DOI 10.1016/j.clinthera.2008.05.018.
27. Марковская А. И., Гаймоленко И. Н., Потапова Н. Л. Профилактическое применение Монтелукаста у детей группы риска развития бронхиальной астмы // Сиб. мед. обозрение. 2020. № 4. С. 49–55. DOI 10.20333/2500136-2020-4-49-55.
28. Hussein H. R., Gupta A., Broughton S., Ruiz G., Brathwaite N., Bossley C. J. A Meta-Analysis of Montelukast for Recurrent Wheeze in Prescho ol Children // Eur J Pediatr. 2017. Vol. 176, Is. 7. P. 963–969. DOI 10.1007/s00431-017-2936-6.
29. Keskin O., Yilmaz E. A., Motzkus C., Sackesen C., Lily S. M., Kalayci O. The Effect of Montelukast on Early-Life Wheezing: A Randomized,
30. Double-Blinded Placebo-Controlled Study // Pediatr Allergy Immunol. 2018. Vol. 29, Is. 1. P. 50–57. DOI 10.1111/pai.12822.
31. Тихонова Н. К., Литвиненко С. Н., Тихонов В. Г. Опыт профилактического применения пролонгированных курсов монтелукаста у детей группы риска по возникновению бронхиальной астмы // Вестник Смолен. гос. мед. акад. 2019. № 18 (3). С. 241–246.
32. Stasi C., Fallani S., Voller F., Silvestri C. Treatment for COVID-19: An Overview // Eur J Pharmacol. 2020. Vol. 889. P. 173644. DOI 10.1016/j.ejphar.2020.173644.
33. Hojyo S., Uchida M., Tanaka K. et al. How COVID-19 Induces Cytokine Storm with High Mortality // Inflamm Regen. 2020. Vol. 40. P. 37. DOI 10.1186/s41232-020-00146-3.
34. Wu C., Liu Y., Yang Y. et al. Analysis of Therapeutic Targets for SARSCoV-2 and Discovery of Potential Drugs by Computational Methods
35. // Acta Pharm Sin B. 2020. Vol. 10, Is. 5. P. 766–788. DOI 10.1016/ j.apsb.2020.02.008.
36. Qamar M. T., Alqahtani S. M., Alamri M. A., Chen L.-L. Structural Basis
37. of SARS-CoV-2 3CLpro and Anti-COVID-19 Drug Discovery from Medicinal Plants // J Pharm Anal. 2020. Vol. 10, Is. 4. P. 313–319. DOI 10.1016/j.jpha.2020.03.009.
38. Copertino D. C., Duarte R. R. R., Powell T. R., de Mulder Rougvie M., Nixon D. F. Montelukast Drug Activity and Potential against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) // J Med Virol. 2021. Vol. 93, Is. 1. P. 187–189. DOI 10.1002/jmv.26299.
39. Sharifinejad N., Sharafian S., Salekmoghadam S., Tavakol M., Qorbani M. Montelukast and Coronavirus Disease 2019: A Scoping Review // Iran J Allergy Asthma Immunol. 2021. Vol. 20, Is. 4. P. 384–393.
40. Almerie M. Q., Kerrigan D. D. The Association between Obesity and Poor Outcome after COVID-19 Indicates a Potential Therapeutic Role for Montelukast // Med Hypotheses. 2020. Vol. 143. P. 109883. DOI 10.1016/j.mehy.2020.109883.
41. Khan A. R., Misdary Ch., Yegya-Raman N. et al. Montelukast in Hospitalized Patients Diagnosed with COVID-19 // J Asthma. 2022. Vol. 59, Is. 4. P. 780–786. DOI 10.1080/02770903.2021.1881967.
42. Lin Y.-C., Huange M.-Y., Lee M.-S. et al. Effects of Montelukast on M2 Related Cytokine and Chemokine in M2 Macrophages // J Microbiol Immunol Infect. 2018. Vol. 51, Is. 1. P. 18–26. DOI 10.1016/j.jmii.2016.04.005.
Review
For citations:
Markovskaya A.L., Potapova N.L., Mizernitsky Yu.L. CORONAVIRUS INFECTION: PROSPECTS OF MONTELUKAST AS A THERAPEUTIC AND PROPHYLACTIC AGENT. Vestnik SurGU. Meditsina. 2022;(2 (52)):69-73. (In Russ.) https://doi.org/10.34822/2304-9448-2022-2-69-73
Views:
119
Email this article 
